Skip to main content

Table 1 Patient characteristics of the ST-ICI cohort

From: Questionnaire-based detection of immune-related adverse events in cancer patients treated with PD-1/PD-L1 immune checkpoint inhibitors

Patient characteristics

All patients

n = 104 (%)

Sex

 Male

76 (73)

 Female

28 (27)

Median age ± SD (years)

66 ± 10.2

Treatment arm

 IT-RT

50 (48)

 IT-only

54 (52)

Location of radiotherapya (n = 50)

 Lung

17 (34)

 CNS

10 (20)

 Bone

5 (10)

 Other

18 (36)

PD-L1 tumor cells

 < 1%

36 (35)

 1–49%

33 (32)

 ≥ 50%

32 (31)

 Unknown

3 (3)

Brain metastases

24 (23)

Tumor entity

 NSCLC

46 (44)

 HNSCC

44 (42)

 Bladder cancer

5 (5)

 Oesophageal cancer

4 (4)

 Other

5 (5)

Number of previous treatments

 0–1

61 (59)

  ≥ 2

43 (41)

Disease stage

 

Adjuvant setting

12 (12)

Palliative setting

92 (88)

  local tumor recurrence

15 (14)

  distant metastases

77 (74)

Drug

 Nivolumab

66 (64)

 Pembrolizumab

24 (23)

 Durvalumab

9 (9)

 Other

5 (5)

Concomitant chemotherapy

6 (6)

Comorbidityb (n = 199)

 Arterial hypertonia

34 (33)

 Cardiovascular comorbidity

30 (29)

 Diabetes

20 (19)

 COPD

18 (17)

 Autoimmune disease

2 (2)

 Other

87 (84)

 None

8 (8)

  1. aOnly radiotherapy within 30 days before or after first administration of ICI
  2. bMultiple co-morbidities per patient possible
  3. SD Standard deviation, IT Immunotherapy, RT Radiotherapy, CNS Central nervous system, PD-L1 Programmed death ligand, HNSCC Head and neck squamous cell carcinoma, NSCLC Non small cell lung carcinoma